Importantly, genetic ablation of HSD11B2 reduced the size of medulloblastoma in the SmoM transgenic mouse model, suggesting that HSD11β2 inhibitors might be applied as cilia-related cancer therapies (Daggubati et al., 2021). The gene discussed is HSD11B2; the disease is cancer.